

Mean Paw Compression Thresholds (g)
180
160
140
120
100
80
60
Vehicle
Zoledronic acid 18 mg/m sq.
Zoledronic acid 120 mg/m sq.
Zoledronic acid 900 mg/m sq.
Day 1 BL
Day 1 (0.5hr)
Day 1 (1hr)
Day 1 (3hr)
Day 2 BL
Day 2 (1hr)
Day 3 BL
Day 3 (1hr)

FIG. 1



60%
50%
40%
30%
20%
10%
0%
% Reversal of Arthritis Pain
Zoledronic acid 54 mg/m2
Zoledronic acid 360 mg/m2

FIG. 2A



Pain Threshold (g)
290
270
250
230
210
190
170
150
Normal Paw
Vehicle
Zoledronic acid 54 mg/m2
Zoledronic acid 360 mg/m2

FIG. 2B



60
45
30
15
0
-15
-30
-45
-60
-75
-90
% Change vs. control
Pain
Edema
Warmth
Weight Bearing

FIG. 3



Hindpaw Pain Threshold (g)
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0
Vehicle
Zoledronic acid
Left Paw (Normal)
Right Paw (Fracture)

FIG. 4



100
90
80
70
60
50
40
30
20
10
0
Weight Bearing (%)
Vehicle
Zoledronic acid

FIG. 5



Paw Thickness Change (mm)
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Vehicle
Zoledronic acid

FIG. 6



14
12
10
8
6
4
2
0
Solubility (g/100 mL)
Zoledronic acid
Disodium zoledronate tetrahydrate

FIG. 7



2000
1800
1600
1400
1200
1000
800
600
400
200
0
Zoledronic Acid Plasma Concentration (ng/mL)
0
1
2
3
4
5
6
Time (hour)
150 mg - Disodium zoledronate
150 mg - Zoledronic acid

FIG. 8



20
18
16
14
12
10
8
6
4
2
0
Tablet Hardness (kPa)
0
1000
2000
3000
4000
5000
6000
Compression Force (psi)
50 mg Disodium Salt
50 mg Diacid
71 mg Disodium Salt

FIG. 9



Change in VAS Pain Score Compared to Placebo with Zoledronic Acid Treatment
OARSI Grade 0
OARSI Grade 1-2
0.0
-2.0
-4.0
-6.0
-8.0
-10.0
-12.0
-14.0
-16.0
VAS Change vs. Placebo (mm)

FIG. 10



Change in VAS Pain Score Compared to Baseline with Zoledronic Acid Treatment
OARSI Grade 0
OARSI Grade 1
OARSI Grade 2
0.0
-5.0
-10.0
-15.0
-20.0
-25.0
VAS Change vs. Baseline (mm)

FIG. 11



Change in VAS Pain Score Compared to Placebo with Zoledronic Acid Treatment at Three Months
All patients
Baseline VAS ≥ 50
OARSI Grade 0
Baseline VAS ≥ 50 + OARSI Grade 0
VAS Change vs. Placebo (mm)
0.0
-2.0
-4.0
-6.0
-8.0
-10.0
-12.0
-14.0
-16.0
-18.0
-20.0

FIG. 12



Change in BML Lesion Size Compared to Placebo with Zoledronic Acid Treatment
OARSI Grade 0
OARSI Grade 1-2
0.0
-20.0
-40.0
-60.0
-80.0
-100.0
-120.0
-140.0
-160.0
-180.0
-200.0
BML Area Change vs. Placebo (mm²)

FIG. 13